Shishi Pharmaceutical Group

CSPC Pharmaceutical Group is a leading integrated pharmaceutical enterprise in China, specializing in the research, development, manufacturing, and marketing of innovative drugs. The company has successfully transitioned from a major manufacturer of active pharmaceutical ingredients and generics to an innovation-driven biopharmaceutical leader. Its diverse portfolio covers key therapeutic areas including oncology, cardiovascular, cerebrovascular, and neurology, with flagship products like NBP (butylphthalide) for stroke. CSPC leverages advanced technology platforms such as mRNA vaccines, antibody-drug conjugates (ADCs), and nano-formulations to drive its robust R&D pipeline. With a significant global presence and large-scale manufacturing capabilities, the group is a pivotal player in both the international pharmaceutical supply chain and the development of next-generation biologics.